Literature DB >> 10335984

The beta+-thalassemia mutation [IVS-II-5 (G-->C] creates an alternative splicing site in the second intervening sequence.

N H Jiang1, S Liang.   

Abstract

We report a beta-thalassemia mutation [IVS-II-5 (G-->C)] in a Chinese family. Recently we cloned this beta-globin gene and studied its transient expression in murine erythroleukemia (MEL) cells. Both the thalassemic and normal beta-globin genes were isolated by polymerase chain reaction and TA-vector cloning. When the cloned beta-thalassemic globin gene was introduced into MEL cells, two kinds of spliced cytoplasmic beta-globin RNAs were detected. The predominant RNA was normally spliced, while the less abundant RNA contained an insertion of the first 47 nucleotides of the second intervening sequence localized between exons 2 and 3. These results suggest that the mutation [IVS-II-5 (G-->C)] causes a beta+-thalassemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10335984     DOI: 10.3109/03630269908996161

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  2 in total

1.  The Clinical Significance of the Spectrum of Interactions of the Rare IVS-II-5 G>C (HBB: c.315+5 G>C) Variation with Other β-Thalassemia Mutations in Southern China.

Authors:  Guiping Liao; Yali Zhou; Xiaolin Yin; Sheng He; Yi Wu; Jian Xiao; Zhili Geng; Qiuying Huang; Ganghui Luo; Kun Yang
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

2.  The Scope for Thalassemia Gene Therapy by Disruption of Aberrant Regulatory Elements.

Authors:  Petros Patsali; Claudio Mussolino; Petros Ladas; Argyro Floga; Annita Kolnagou; Soteroula Christou; Maria Sitarou; Michael N Antoniou; Toni Cathomen; Carsten Werner Lederer; Marina Kleanthous
Journal:  J Clin Med       Date:  2019-11-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.